Literature DB >> 32350883

Role of imaging in multiple myeloma.

Francis I Baffour1, Katrina N Glazebrook1, Shaji K Kumar2, Stephen M Broski1.   

Abstract

With rapid advancements in the diagnosis and treatment of multiple myeloma (MM), imaging has become instrumental in detection of intramedullary and extramedullary disease, providing prognostic information, and assessing therapeutic efficacy. Whole-body low dose computed tomography (WBLDCT) has emerged as the study of choice to detect osteolytic bone disease. Positron emission tomography/computed tomography (PET/CT) combines functional and morphologic information to identify MM disease activity and assess treatment response. Magnetic resonance imaging (MRI) has excellent soft-tissue contrast and is the modality of choice for bone marrow evaluation. This review focuses on the imaging modalities available for MM patient management, highlighting advantages, disadvantages, and applications of each.
© 2020 Wiley Periodicals, Inc.

Entities:  

Year:  2020        PMID: 32350883     DOI: 10.1002/ajh.25846

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

Review 1.  Progress of modern imaging modalities in multiple myeloma.

Authors:  Toshiki Terao; Kosei Matsue
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.490

2.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis.

Authors:  Qian Li; Linhui Hu; Alice Charwudzi; Weiwei Zhu; Ye Meng; Zhimin Zhai
Journal:  Clin Exp Med       Date:  2022-01-09       Impact factor: 3.984

Review 3.  Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting.

Authors:  Giulia Ferrarazzo; Silvia Chiola; Selene Capitanio; Maria Isabella Donegani; Alberto Miceli; Stefano Raffa; Alberto Stefano Tagliafico; Silvia Morbelli; Matteo Bauckneht
Journal:  Diagnostics (Basel)       Date:  2021-02-03

Review 4.  Imaging for Plasma Cell Dyscrasias: What, When, and How?

Authors:  Amrita Guha; Antariksh Vijan; Ujjwal Agarwal; Jayant Sastri Goda; Abhishek Mahajan; Nitin Shetty; Navin Khattry
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

5.  FDG PET-MRI evaluation of synchronous gallbladder adenocarcinoma and POEMS syndrome.

Authors:  Fatemeh Ataei; Akash Sharma; Rupert Stanborough; Ephraim E Parent
Journal:  Radiol Case Rep       Date:  2022-09-13

6.  Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study.

Authors:  Liping Li; Xiaofeng Li; An Shang; Yan Zhao; Lifang Jin; Meng Zhao; Weizhang Shen
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

Review 7.  Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging.

Authors:  Karla M Treitl; Jens Ricke; Andrea Baur-Melnyk
Journal:  Skeletal Radiol       Date:  2021-05-24       Impact factor: 2.199

Review 8.  Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.

Authors:  Frederic E Lecouvet; Marie-Christiane Vekemans; Thomas Van Den Berghe; Koenraad Verstraete; Thomas Kirchgesner; Souad Acid; Jacques Malghem; Joris Wuts; Jens Hillengass; Vincent Vandecaveye; François Jamar; Olivier Gheysens; Bruno C Vande Berg
Journal:  Skeletal Radiol       Date:  2021-08-07       Impact factor: 2.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.